Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.

Autor:	Gürbüz M; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey., Kiliçkap S; İstinye University Faculty of Medicine, Liv Ankara Hospital, Department of Medical Oncology, Ankara, Turkey., Bilici A; İstanbul Medipol University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey., Karadurmuş N; University of Health Sciences, Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey., Sezer A; Başkent University Faculty of Medicine, Department of Medical Oncology, Adana, Turkey., Şendur MAN; Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey., Paydaş S; Çukurova University Faculty of Medicine, Department of Medical Oncology, Adana, Turkey., Artaç M; Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey., Fulden Yumuk P; Koç University Hospital, Department of Medical Oncology, Istanbul, Turkey., Gürsoy P; Ege University Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey., Uysal M; Medstar Antalya Hospital, Department of Medical Oncology, Antalya, Turkey., Şenol Coşkun H; Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey., Tatli AM; Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey., Selçukbiricik F; Koç University Hospital, Department of Medical Oncology, Istanbul, Turkey., Dişel U; Acibadem Adana Hospital, Department of Medical Oncology, Adana, Turkey., Köksoy EB; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey., Güven DC; Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey., Uğrakli M; Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey., Akkuş E; Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey., Yücel Ş; Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey., Erol C; Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey., Karakaya S; Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey., Şakalar T; Necip Fazil City Hospital, Department of Medical Oncology, Kahramanmaraş, Turkey., Khanmammadov N; İstanbul University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey., Paksoy N; Tekirdağ Dr. İsmail Fehmi Cumalioğlu City Hospital, Department of Medical Oncology, Tekirdağ, Turkey., Demirkazik A; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2022 Dec 16; Vol. 101 (50), pp. e32368.
DOI:	10.1097/MD.0000000000032368
Abstrakt:	Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n = 33) and 46.8% (n = 29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P = .217). Median PFS was significantly longer in patients who have never smoked (P = .040), have good performance score (P < .001), and responded to the treatment (P < .001). OS was significantly longer in patients with MET mutation (25.6 months, 95% CI: 15.9-35.3) compared to the patients with MET amplification (11.0 months; 95% CI: 5.2-16.8) (P = .049). In never-smokers, median OS was longer than smoker patients (25.6 months [95% CI: 11.8-39.3] vs 16.5 months [95% CI: 9.3-23.6]; P = .049). The most common adverse effects were fatigue (50%), peripheral edema (21%), nausea (29%) and diarrhea (19.4%). Grade 3 or 4 adverse effects were observed in 6.5% of the patients. This real-life data confirms efficacy and safety of crizotinib in the treatment of advanced NSCLC harboring MET alteration. Competing Interests: The authors have no funding and conflicts of interest to disclose. (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu